Share on StockTwits

Equities researchers at BMO Capital Markets lowered their target price on shares of Kindred Biosciences (NYSE:KIN) from $30.00 to $19.00 in a research report issued on Thursday. BMO Capital Markets’ target price suggests a potential upside of 30.05% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Leerink Swann cut their price target on shares of Kindred Biosciences from $29.00 to $11.25 in a research note on Thursday. Separately, analysts at Roth Capital cut their price target on shares of Kindred Biosciences to $11.50 in a research note on Thursday. Finally, analysts at Craig Hallum initiated coverage on shares of Kindred Biosciences in a research note on Friday, May 23rd. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $13.92.

Kindred Biosciences (NYSE:KIN) traded down 26.21% on Thursday, hitting $10.485. 1,598,574 shares of the company’s stock traded hands. Kindred Biosciences has a 52 week low of $8.75 and a 52 week high of $26.99. The stock’s 50-day moving average is $15.89 and its 200-day moving average is $18.09. The company’s market cap is $206.7 million.

Kindred Biosciences (NYSE:KIN) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.07. Analysts expect that Kindred Biosciences will post $-1.75 EPS for the current fiscal year.

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.